Abstract
A growing number of companies and academic groups are reporting impressive
progress in commercializing new sequencing platforms that offer orders of
magnitude of improved throughput and cost. The prospect of routine,
personalized genome sequencing is suddenly within reach, not to mention
spectacular advances in a host of related fields.
This new report from CHI Insight Pharma Reports describes and assesses these developing technologies and their applications:
- Pyrosequencing
- Sequencing by synthesis
- Supported oligonucleotide detection (SOLiD)
- Single-molecule sequencing
- Nanopore sequencing
- Optical trapping
Next-Generation Sequencing: Scientific and Commercial Implications of the
$1000 Genome also includes the results and analysis of a quantitative Web
survey of the views, practices, and plans of individuals at life science
organizations involved with gene sequencing.
The applications covered in this report include:
- Personal genomics
- The Cancer Genome Atlas
- Evolutionary genomics
- Environmental genomics
The report also describes the efforts and progress of the companies that have
become leaders in the next-generation sequencing race, including:
- Applied Biosystems
- GE Healthcare
- Helicos BioSciences
- Illumina/Solexa
- Reveo
- Roche/454 Life Sciences
- VisiGen Biotechnologies
Next-Generation Sequencing: Scientific and Commercial Implications of the
$1000 Genome is an essential tool for individuals involved in R&D or
commercialization of next-generation sequencing technologies.
| 
View Cart
